Ovarian Cancer Article in NY Times
As I was drinking my morning coffee I found an interesting article that was published in the New York Times regarding the use of the kidney cancer drug Votrient (pazopanib) as maintenance therapy for women with ovarian cancer who have responded successfully to chemotherapy. The results of the study show this drug does increase the time a patient is in remission by an average of five months. The population targeted was a specialized group of women, but nonetheless this is an exciting discovery for the advanced treatment of ovarian cancer.